Source link : https://newshealth.biz/health-news/parp-arpi-combo-sets-new-standard-for-metastatic-hormone-sensitive-prostate-cancer/
(MedPage Today) — CHICAGO — Men with homologous recombination repair (HRR)-deficient, metastatic, castration-sensitive prostate cancer (mCSPC) lived significantly longer without disease progression when they received a PARP inhibitor in addition… Source link : https://www.medpagetoday.com/meetingcoverage/asco/115861 Author : Publish date : 2025-06-03 12:00:00 Copyright for syndicated content belongs to the linked Source.
The post PARP-ARPI Combo Sets New Standard for Metastatic Hormone-Sensitive Prostate Cancer first appeared on News Health.
—-
Author : News Health
Publish date : 2025-06-03 12:00:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8